{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=New+Haven&page=12&state=Connecticut", "query": { "state": "Connecticut", "city": "New Haven", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 1348, "total_pages": 135, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=New+Haven&page=13&state=Connecticut&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=New+Haven&page=11&state=Connecticut&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T10:50:02.076Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03028740", "title": "AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Nonalcoholic Steatohepatitis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Cenicriviroc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tobira Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1778, "start_date": "2017-04-05", "completion_date": "2021-03-09", "has_results": true, "last_update_posted_date": "2022-03-10", "last_synced_at": "2026-10-31T10:50:02.076Z", "location_count": 204, "location_summary": "Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 144 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Madison", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03028740" }, { "nct_id": "NCT04268550", "title": "Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Selpercatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 124, "start_date": "2020-04-08", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-10-31T10:50:02.076Z", "location_count": 306, "location_summary": "Fairbanks, Alaska • Little Rock, Arkansas • Anaheim, California + 251 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Auburn", "state": "California" }, { "city": "Baldwin Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04268550" }, { "nct_id": "NCT04457596", "title": "T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "HER2 Positive Breast Carcinoma", "Invasive Breast Carcinoma", "Multifocal Breast Carcinoma", "Synchronous Bilateral Breast Carcinoma", "Anatomic Stage I Breast Cancer AJCC v8" ], "interventions": [ { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1056, "start_date": "2021-03-02", "completion_date": "2035-05-31", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-31T10:50:02.076Z", "location_count": 1160, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 749 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04457596" }, { "nct_id": "NCT05554627", "title": "VA Aripiprazole vs Esketamine for Treatment Resistant Depression", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Depressive Disorder, Major" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 0, "start_date": "2023-10-27", "completion_date": "2023-10-27", "has_results": false, "last_update_posted_date": "2024-01-05", "last_synced_at": "2026-10-31T10:50:02.076Z", "location_count": 26, "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05554627" }, { "nct_id": "NCT03402256", "title": "Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alcoholic Liver Disease" ], "interventions": [ { "name": "Text Message", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2013-03-22", "completion_date": "2014-05-06", "has_results": false, "last_update_posted_date": "2018-01-18", "last_synced_at": "2026-10-31T10:50:02.076Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03402256" }, { "nct_id": "NCT03907046", "title": "Anticoagulation in ICH Survivors for Stroke Prevention and Recovery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Intracerebral Hemorrhage", "Atrial Fibrillation" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 700, "start_date": "2020-01-28", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-31T10:50:02.076Z", "location_count": 186, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03907046" }, { "nct_id": "NCT01719380", "title": "Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "LGX818", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "BYL719", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2012-11-23", "completion_date": "2019-02-12", "has_results": true, "last_update_posted_date": "2021-06-23", "last_synced_at": "2026-10-31T10:50:02.076Z", "location_count": 32, "location_summary": "Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01719380" }, { "nct_id": "NCT03398473", "title": "A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Epoetin Hospira SDV", "type": "DRUG" }, { "name": "Epoetin Hospira MDV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 68, "start_date": "2018-01-25", "completion_date": "2018-05-07", "has_results": false, "last_update_posted_date": "2018-05-17", "last_synced_at": "2026-10-31T10:50:02.076Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03398473" }, { "nct_id": "NCT03377556", "title": "Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ATM Gene Mutation", "ATR Gene Mutation", "BARD1 Gene Mutation", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "BRIP1 Gene Mutation", "CHEK1 Gene Mutation", "CHEK2 Gene Mutation", "FANCA Gene Mutation", "FANCC Gene Mutation", "FANCD2 Gene Mutation", "FANCF Gene Mutation", "FANCM Gene Mutation", "NBN Gene Mutation", "PALB2 Gene Mutation", "RAD51 Gene Mutation", "RAD51B Gene Mutation", "RAD54L Gene Mutation", "Recurrent Squamous Cell Lung Carcinoma", "RPA1 Gene Mutation", "Stage IV Squamous Cell Lung Carcinoma AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 51, "start_date": "2017-03-03", "completion_date": "2021-04-16", "has_results": true, "last_update_posted_date": "2021-06-23", "last_synced_at": "2026-10-31T10:50:02.076Z", "location_count": 1151, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 713 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03377556" }, { "nct_id": "NCT04717375", "title": "Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Neoplasm" ], "interventions": [ { "name": "SAR444881", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2021-04-11", "completion_date": "2025-07-02", "has_results": true, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-31T10:50:02.076Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Duarte, California • Aurora, Colorado + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Clermont", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04717375" } ] }